- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Heart Failure Society of America
The Heart Failure Society of America annual scientific meeting features the latest in management and late-breaking clinical data related to heart failure.
Furosemide Injection Could Improve Congestion Management in Heart Failure Without Need for Hospitalization
October 07, 2022
Data from the AT-HOME HF pilot study presented at HFSA 2022 provide insight into the effects of furosemide injection 8 mg/mL on congestion management among patients with heart failure ahead of the agent's October 8 PDUFA date.
Trends in Device Therapy for Heart Failure, with Andrew Sauer, MD
October 06, 2022
At HFSA 2022, Andrew Sauer, MD, provides perspective on contemporary trends in device therapy in heart failure, including recommendations made within the 2022 ACC/AHA/HFSA heart failure guidelines.
Understanding Aficamten and the SEQUOIA-HCM Design, with Martin Maron, MD
October 05, 2022
Martin Maron, MD, sits down to discuss aficamten, the SEQUOIA-HCM trial, and the most pressing unmet needs in the management of hypertrophic cardiomyopathy.
8-in-10 Medicare Beneficiaries Hospitalized with HFpEF Could be Considered Candidates for Dapagliflozin
October 04, 2022
An analysis applying data from the DELIVER trial to the Get With The Guidelines-Heart Failure Registry suggests 81% of hospitalized Medicare beneficiaries with HFpEF could be considered candidates for dapagliflozin use under a potential FDA label expansion.
Dapagliflozin's Benefit in HFpEF Reaches Significance Within 2 Weeks, Study Finds
October 03, 2022
A prespecified analysis of the DELIVER trial presented at HFSA 2022 indicates dapagliflozin provides early benefit in patients with heart failure with preserved ejection fraction, with the effect on the trial's primary end point evident in just 13 days.
Sacubitril/Valsartan Use Could Reduce Mitral Regurgitation in HFrEF
October 03, 2022
An analysis of data from the PROVE-HF trial suggests use of sacubitril/valsartan was associated with a reduction in prevalence of mitral regurgitation among patients with heart failure with reduced ejection fraction.
Aficamten Could Improve Quality of Life, Symptom Burden in Hypertrophic Cardiomyopathy
October 02, 2022
Data presented at HFSA 2022 examining aficamten provides insight into the effects of the agent on LVOT-G, NYHA class, and KCCQ-OSS among patients with hypertrophic cardiomyopathy from the open-label extension trial.
Optimizing Initiation of GDMT for Heart Failure, with Stephen Greene, MD
October 02, 2022
After a presentation on cost considerations and outcomes at HFSA 2022, Stephen Greene, MD, provides perspective on the current state of optimization for GDMT in heart failure.
Sotagliflozin Reduces Risk of Recurrent Heart Failure Events
October 02, 2022
New sotagliflozin data at HFSA 2022 provides insight into the apparent reduction in recurrent heart failure events achieved in the SOLOIST-WHF trial. Deepak Bhatt, MD, MPH, provides perspective on the potential role of the dual SGLT1/2 inhibitor, based on trial data, if approved by the US Food and Drug Administration.
Rates of Sudden Cardiac Death in Hypertrophic Cardiomyopathy Falling in Recent Years
October 01, 2022
Martin Maron, MD, provides perspective on a recent study he led examining changes in rate of sudden cardiac death among patients with hypertrophic cardiomyopathy and reflects on the progress made within disease management.